Ana P. Kutschat

Impact of primary kidney disease on the effects of empagliflozin in patients with chronic kidney disease: secondary analyses of the EMPA-KIDNEY trial

PK Judge, Natalie Staplin, KJ Mayne et al. · The Lancet Diabetes & Endocrinology · 2023 · 108 citations · Full text

Medicine, Nephrology, Pharmacotherapy +11

Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial

Natalie Staplin, Richard Haynes, PK Judge et al. · The Lancet Diabetes & Endocrinology · 2023 · 90 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

ARID1A facilitates KRAS signaling-regulated enhancer activity in an AP1-dependent manner in colorectal cancer cells

Madhobi Sen, Xin Wang, Feda H. Hamdan et al. · Clinical Epigenetics · 2019 · 63 citations · Full text

Medicine, Molecular Genetics, Oncology +17

Bromodomain protein BRDT directs ΔNp63 function and super-enhancer activity in a subset of esophageal squamous cell carcinomas

Xin Wang, Ana P. Kutschat, Moyuru Yamada et al. · Cell Death and Differentiation · 2021 · 28 citations · Full text

Medicine, Genetics, Oncology +17

The histone deacetylase HDAC1 controls dendritic cell development and anti-tumor immunity

Cristiano De Sá Fernandes, Philipp Novoszel, Tommaso Gastaldi et al. · Cell Reports · 2024 · 28 citations · Full text

Life Sciences, Immunology, Molecular Biology +16